HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
21 hedge funds and large institutions have $3.19M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
5.12% less ownership
Funds ownership: 35.38% → 30.25% (-5.1%)
78% less capital invested
Capital invested by funds: $14.5M → $3.19M (-$11.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.23M |
| 2 |
Millennium Management
New York
|
+$73.5K |
| 3 |
Morgan Stanley
New York
|
+$31.9K |
| 4 |
Citigroup
New York
|
+$8.02K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$3.32M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$776K |
| 3 |
CPA
Cowen Prime Advisors
New York
|
-$698K |
| 4 |
SC
Samjo Capital
New York
|
-$495K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$131K |
HTGM Hedge Fund Activity: Q1 2022 in Review
21 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q1 2022, worth a combined $3.19M — down 78% from $14.5M a quarter earlier.
Fund positioning in HTGM was balanced in Q1 2022: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 3 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.23M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $3.32M sold.
- 21 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $3.19M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q1 2022, down 78% quarter-over-quarter.
- 5 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q1 2022 and 5 closed out, a net change of 0 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q1 2022 was Armistice Capital, an estimated $2.23M added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q1 2022 was AIGH Capital Management, an estimated $3.32M sold.
Based on aggregated 13F filings for Q1 2022.